MedImmune High Court Decision Could Carry Extra Weight For Generic Firms

The U.S. Supreme Court's refusal to hear a case brought by Apotex against Pfizer could increase the importance of its upcoming decision in MedImmune v. Genentech to provide clarity on exclusivity forfeiture provisions for generic firms